Efficacy and Safety of Epanova (Omefas) in Severe Hypertriglyceridemia.

Trial Profile

Efficacy and Safety of Epanova (Omefas) in Severe Hypertriglyceridemia.

Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Omega-3 carboxylic acids (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 May 2014 According to an AstraZeneca media release, FDA approval was granted for Epanova based on data that included results from this trial.
    • 09 Jul 2013 Positive results from this trial are included in the NDA submission to the FDA for Epanova for the treatment of patients with very high triglyceride levels, according to an Omthera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top